The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…Effectiveness of Opicapone Added to Different Levodopa Doses and LEDDs in Parkinson’s Disease: Post-Hoc Analysis of the ADOPTION Trials
Objective: To assess the efficacy of opicapone 50 mg, compared to an additional 100 mg dose of levodopa, in reducing OFF-time in Parkinson’s disease (PD)…Dual-task gait digital assessment unmask the association between dopaminergic deficits and gait parameters in early and prodromal Parkinson’s Disease
Objective: to explore the relationship between dopaminergic deficits and digital gait parameters alterations in de novo PD and iRBD Background: gait alterations are common features…LRRK2 Pathway Inhibition By NEU-411, a Potent, Selective, CNS-Penetrant LRRK2 Inhibitor In Healthy Participants
Objective: The aim of this work was to evaluate LRRK2 pathway modulation by the potent, selective, CNS-penetrant LRRK2 inhibitor NEU-411 in healthy adults and elderly…Efficacy And Safety of Fecal Microbiota Transplant for Parkinson’s Disease: A Systematic Review And Meta-Analysis
Objective: To evaluate the efficacy and safety of Fecal Microbiota Transplantation (FMT) in patients with Parkinson’s disease (PD). Background: FMT is a novel therapy for…Inpatient Multimodal Care Improves Parkinsonian Symptoms Regardless Of Race Or Ethnicity
Objective: To verify demographic characteristics of patients with Parkinson’s disease (PD) completing a two-week inpatient multimodal intensive neurorehabilitation and care (iMINC) program and whether iMINC…Adaptive deep brain stimulation for tremor control in Parkinson’s disease
Objective: To evaluate clinical improvements in tremor following the implementation of adaptive deep brain stimulation (aDBS). Background: Alpha-beta (8-30Hz) based aDBS is a safe and…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations
Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…EJS ACT-PD: An Ongoing Initiative to Support Innovation and Sustainability of a Multi-Arm, Multi-Stage Platform Trial for Parkinson’s Disease
Objective: To provide continued consortium expertise to provide ongoing innovation and long-term sustainability in a multi-arm, multi-stage (MAMS) disease modification trial for Parkinson’s disease (PD).…
- « Previous Page
- 1
- …
- 301
- 302
- 303
- 304
- 305
- …
- 1942
- Next Page »